← Oncology Approval Tracker

FDA DECISION ·

Tibsovo

ivosidenib · Servier Pharmaceuticals

FDA approvalNew or expanded indicationCholangiocarcinoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with previously treated locally advanced or metastatic cholangiocarcinoma with an IDH1 mutation confirmed by an FDA-approved test.

LAMPGEN ANALYSIS

Why it matters

The decision extends IDH1 inhibition from hematologic disease to an anatomically and molecularly defined biliary cancer population.

What research teams should watch

Retain the molecular report and prior systemic treatment and coordinate electrocardiogram monitoring.

PRIMARY RECORDS

Sources